Bicara Therapeutics CFO files initial Form 3

Bicara Therapeutics Inc. reported the initial insider ownership status of its Chief Financial Officer, Jennifer Larson, through a Form 3.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. reported the initial insider ownership status of its Chief Financial Officer, Jennifer Larson, through a Form 3. The filing lists her as an officer but shows no reportable equity holdings or transactions at this time. It also references an attached Exhibit 24 granting a Power of Attorney.

Key Terms

Power of Attorney

1 terms

Power of Attorney regulatory

"Remarks note: "Exhibit 24 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Bicara Therapeutics (BCAX) Form 3 for Jennifer Larson show?

The Form 3 for Bicara Therapeutics (BCAX) lists Jennifer Larson as Chief Financial Officer with no reportable equity holdings or transactions disclosed at the time of filing. It serves as her initial ownership statement.

Is Jennifer Larson of Bicara Therapeutics (BCAX) reported as an officer or director?

Jennifer Larson is reported as an officer, serving as Chief Financial Officer of Bicara Therapeutics (BCAX). She is not listed as a director or 10% owner in this Form 3.

Does the Bicara Therapeutics (BCAX) Form 3 report any insider stock transactions?

No. The Bicara Therapeutics (BCAX) Form 3 for Jennifer Larson reports no insider stock transactions, with all transaction counts and share amounts shown as zero in the summary data.

Are any current share holdings reported for Jennifer Larson at Bicara Therapeutics (BCAX)?

The Form 3 indicates no reportable holdings for Jennifer Larson, as the holding entries count is zero. It does not list any specific direct or indirect equity positions.

What is the purpose of Exhibit 24 in the Bicara Therapeutics (BCAX) Form 3?

The remarks section references “Exhibit 24 - Power of Attorney,” indicating a separate document authorizing another party to act on Jennifer Larson’s behalf in connection with certain SEC filing matters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:54 PM Accepted by SEC EDGAR 08/14/2026 - 04:53 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Larson Jennifer

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/12/2026

3. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Ryan Cohlhepp, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)